Citations

Clear

1011 citation(s) found for "Barry, WT".

Abstract B12: An optimized molecular stool test for colorectal cancer screening: Evaluation of an automated analytic platform and logistic algorithm
Lidgard, Graham P. , Domanico, Michael J. , Bruinsma, Janelle J., Light, James, Oldham-Haltom, Rebecca, Fourrier, Keith D. , Allawi, Hatim T. , Yab, Tracy C. , Simonson, Julie A., Devens, Mary E., Heigh, Russell I., Ahlquist, David A. , Gagrat, Zubin D. , Berger, Barry M.

Mayo Clinic

Cancer Prevention Research | January 23, 2014 | Volume: 5 | Issue: 11_Supplement | Pages: B12-B12

10.1158/1940-6207.prev-12-b12 Get It

Abstract We have demonstrated that colorectal cancer (CRC) and advanced pre-cancers can be detected non-invasively by a manual multi-target stool DNA-based test (sDNA-MT) comprising exfoliated DNA markers (methylated BMP3 and NDRG4, mutant KRAS (7 mutations, codons 12, 13), plus β-actin) and fecal hemoglobin (Hb) (Lidgard, Gastroenterology 2012;142(5);S-770). We now report the clinical performance of this sDNA-MT test using an optimized automated analytic platform and logistic algorithm. This platform could facilitate the routine performance of sDNA-MT for CRC screening by molecular diagnostics capable clinical laboratories. Method: Stool samples were collected from 1003 subjects at 36 study sites after informed consent and prior to colonoscopy bowel preparation from those presenting for average risk CRC screening (283) or surveillance (176) at 2 sites. From referred subjects with CRC, Advanced Adenoma (AA) or Sessile Serrate Adenoma ≥ 1 cm, (SSA) stool was collected at least 7 days post-colonoscopy and prior to surgery or chemo-radiation (135; 21 sites) and similarly for subjects with no neoplastic findings on colonoscopy (Neg) (409; 13 sites). The study population included: cases (207), 58% male, median age 65 yrs. (38-87), CRC (93), AA (84), SSA ≥ 1 cm (30) and controls (796), 42% male, median age 65 yrs. (50-84), Neg (641) and non-advanced adenomas (NA) (155). Stool sample collection and DNA isolation were previously described. Automated methylation, mutation and actin assays were performed with a Hamilton STARlet fluid handler (Hamilton Robotics, Reno NV), and QuARTS (Quantitative Allele-specific Real-time Target and Signal amplification) run on an ABI 7500 FastDx real time thermal cycler (Applied Biosystems, Foster City, CA). Fecal Hb (ng/ml buffer) analysis was performed by automated sandwich ELISA. A “Positive” or “Negative” result was determined with an algorithm that included the methylation and mutation results and a logistic regression score, which combines DNA marker results with Hb and actin results. Algorithm results exceeding a threshold were called “Positive”. The algorithm provided good discriminative ability, stability, sensitivity and specificity. Robustness was tested with computer simulations and statistical techniques (leave-one-out and 10-fold cross validation). Results: At a 90% nominal specificity, sDNA-MT sensitivity was 98% for CRC (91/93) [Stage: I, 95% (20/21), II, 100% (23/23), III 96% (26/27), IV 100% (7/7) and I-III combined 97% (69/71)], 57% (65/114) for precursors ≥1 cm (AA, SSA), and 86% (12/14) for precursors with high grade dysplasia. CRC patients were typically referred to colonoscopy for symptoms and test sensitivity may be elevated relative to that seen with screening. Conclusion: With this study using a novel automated sDNA-MT analytic platform with logistic algorithm, we corroborate our earlier findings using a manual process and demonstrate a platform that allows testing to be performed routinely by molecular diagnostic capable laboratories. The high sensitivity of sDNA-MT for CRC across all stages and for advanced precursors with high-grade dysplasia could lead to improved non-invasive CRC screening performance with wide accessibility to patients. A large multi-site pivotal CRC screening study (DeeP-C study clinicaltrials.gov, NCT01397747) to support such use is underway. Citation Format: Graham P. Lidgard, Michael J. Domanico, Janelle J. Bruinsma, James Light, Zubin D. Gagrat, Rebecca L. Oldham-Haltom, Keith D. Fourrier, Hatim Allawi, Tracy C. Yab, Julie A. Simonson, Mary Devens, Russell I. Heigh, David A. Ahlquist, Barry M. Berger. An optimized molecular stool test for colorectal cancer screening: Evaluation of an automated analytic platform and logistic algorithm. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B12.
Invasive Assessment of Pulmonary Hypertension
Borlaug, Barry A.

Mayo Clinic

Circulation: Heart Failure | January 22, 2014 | Volume: 7 | Issue: 1 | Pages: 2-4

10.1161/circheartfailure.113.000983 | PMID 24449809 Get It

Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure
Zhang, Kathleen W. , French, Benjamin , Khan, Abigail , Plappert, Ted, Sweitzer, Nancy K. , Chirinos, Julio A. , Sutton, Martin St. John, Cappola, Thomas P. , Ky, Bonnie , Fang, James C. , Borlaug, Barry A. , Ky, Bonnie

Mayo Clinic

Journal of the American Heart Association | January 14, 2014 | Volume: 3 | Issue: 1 | Pages: No page available

10.1161/jaha.113.000550 | PMID 24419736 Get It

Background The utility of longitudinal, circumferential, and radial strain and strain rate in determining prognosis in chronic heart failure is not well established. Methods and Results In 416 patients with chronic systolic heart failure, we performed speckle‐tracking analyses of left ventricular longitudinal, circumferential, and radial strain and strain rate on archived echocardiography images (30 frames per second). Cox regression models were used to determine the associations between strain and strain rate and risk of all‐cause mortality, cardiac transplantation, and ventricular‐assist device placement. The area under the time‐dependent ROC curve ( AUC ) was also calculated at 1 year and 5 years. Over a maximum follow‐up of 8.9 years, there were 138 events (33.2%). In unadjusted models, all strain and strain rate parameters were associated with adverse outcomes ( P <0.001). In multivariable models, all parameters with the exception of radial strain rate ( P =0.11) remained independently associated, with patients in the lowest tertile of strain or strain rate parameter having a ≈2‐fold increased risk of adverse outcomes compared with the reference group ( P <0.05). Addition of strain to ejection fraction ( EF ) led to a significantly improved AUC at 1 year (0.697 versus 0.633, P =0.032) and 5 years (0.700 versus 0.638, P =0.001). In contrast, strain rate did not provide incremental prognostic value to EF alone. Conclusions Longitudinal and circumferential strain and strain rate, and radial strain are associated with chronic heart failure prognosis. Strain provides incremental value to EF in the prediction of adverse outcomes, and with additional study may be a clinically relevant prognostic tool.
Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus
DeVault, Kenneth R. , McMahon, Barry P. , Marchese, Michele , Hejazi, Reza , McCallum, Richard W. , Savarino, Vincenzo , Zentilin, Patrizia , Savarino, Edoardo , Thomson, Mike , Souza, Rhonda F. , Donohoe, Claire L. , O’Farrell, Naoimh J. , Reynolds, John V. , DeVault, Kenneth, Çelebi, Altay , Costamagna, Guido , Clarke, John O. , Savarino, Edoardo

Mayo Clinic

Annals of the New York Academy of Sciences | January 6, 2014 | Volume: 1300 | Issue: 1 | Pages: 278-295

10.1111/nyas.12253 | PMID 24117649 Get It

The following paper on gastroesophageal reflux disease (GERD) and Barrett's esophagus (BE) includes commentaries on defining esophageal landmarks; new techniques for evaluating upper esophageal sphincter (UES) tone; differential diagnosis of GERD, BE, and hiatal hernia (HH); the use of high‐resolution manometry for evaluation of reflux; the role of fundic relaxation in reflux; the use of 24‐h esophageal pH–impedance testing in differentiating acid from nonacid reflux and its potential inclusion in future Rome criteria; classification of endoscopic findings in GERD; the search for the cell origin that generates BE; and the relationship between BE, Barrett's carcinoma, and obesity.
Conversations in Cardiology
Applegate, Robert J., Bell, Malcolm R. , Brilakis, Emmanouil S. , Bach, Richard G. , Kaul, Prashant , Klein, Lloyd W. , Krucoff, Mitchell W., Stone, Gregg W. , Kern, Morton J. , Butman, Samuel M. , Moore, Joseph Allen , Price, Matthew J. , Rao, Sunil V. , Uretsky, Barry F. , Brilakis, Emmanouil S

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 13, 2013 | Volume: 83 | Issue: 5 | Pages: 748-752

10.1002/ccd.25319 | PMID 24395180 Get It

Bridging for antiplatelet therapy remains a subject of debate with data favoring GP blockers but at a risk of bleeding. This Conversation in Cardiology addresses a key and often asked question about use of alternatives to P2Y12 agents in patients requiring surgery within 6 months after drug eluting stent implantation. © 2013 Wiley Periodicals, Inc.
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
Greene, Stephen J. , Gheorghiade, Mihai , Pieske, Burkert , Burnett, John C. , Roessig, Lothar, Stasch, Johannes‐Peter, Solomon, Scott D. , Paulus, Walter J. , Borlaug, Barry A. , Vaduganathan, Muthiah , Solomon, Scott David , Butler, Javed

Mayo Clinic

Journal of the American Heart Association | December 12, 2013 | Volume: 2 | Issue: 6 | Pages: No page available

10.1161/jaha.113.000536 | PMID 24334823 Get It

Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
Borlaug, Barry A.

Mayo Clinic

Circulation Journal | December 2, 2013 | Volume: 78 | Issue: 1 | Pages: 20-32

10.1253/circj.cj-13-1103 | PMID 24305634 Get It

Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction
Zakeri, Rosita , McNulty, Steven E., Mohammed, Selma F. , Semigran, Marc J., LeWinter, Martin M. , Hernandez, Adrian F. , Braunwald, Eugene, Redfield, Margaret M. , Borlaug, Barry A. , Lewis, Gregory D. , Deswal, Anita M , Braunwald, Eugene , Hernandez, Adrian , Zakeri, Rosita

Mayo Clinic

Circulation: Heart Failure | October 26, 2013 | Volume: 7 | Issue: 1 | Pages: 123-130

10.1161/circheartfailure.113.000568 | PMID 24162898 Get It

Background— Atrial fibrillation (AF) is common among patients with heart failure and preserved ejection fraction (HFpEF), but its clinical profile and impact on exercise capacity remain unclear. RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in HFpEF) was a multicenter randomized trial testing the impact of sildenafil on peak V O 2 in stable outpatients with chronic HFpEF. We sought to compare clinical features and exercise capacity among patients with HFpEF who were in sinus rhythm (SR) or AF. Methods and Results— RELAX enrolled 216 patients with HFpEF, of whom 79 (37%) were in AF, 124 (57%) in SR, and 13 in other rhythms. Participants underwent baseline cardiopulmonary exercise testing, echocardiogram, biomarker assessment, and rhythm status assessment before randomization. Patients with AF were older than those in SR but had similar symptom severity, comorbidities, and renal function. β-blocker use and chronotropic indices were also similar. Despite comparable left ventricular size and mass, AF was associated with worse systolic (lower EF, stroke volume, and cardiac index) and diastolic (shorter deceleration time and larger left atria) function compared with SR. Pulmonary artery systolic pressure was higher in AF. Patients with AF had higher N-terminal pro-B-type natriuretic peptide, aldosterone, endothelin-1, troponin I, and C-telopeptide for type I collagen levels, suggesting more severe neurohumoral activation, myocyte necrosis, and fibrosis. Peak V O 2 was lower in AF, even after adjustment for age, sex, and chronotropic response, and V E /V CO 2 was higher. Conclusions— AF identifies an HFpEF cohort with more advanced disease and significantly reduced exercise capacity. These data suggest that evaluation of the impact of different rate or rhythm control strategies on exercise tolerance in patients with HFpEF and AF is warranted. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00763867.